PDCD1 and non-small cell lung carcinoma: In patients with advanced non-small cell lung cancer (NSCLC) receiving first-line programmed cell death protein 1 (PD1) therapy, pretreatment total metabolic tumor volume (TMTV) and mean standardized uptake value (SUVmean) are predictive of better tumor responses, and high TMTV is significantly associated with poor overall survival (OS) (8).